A clinical evaluation of ritipenem acoxil in paranasal sinusitis

Abstract

Ritipenem acoxil (RIPM-AC) was clinically evaluated in 61 patients with sinusitis and the following results were obtained:
1) In the 51 patients in whom clinical efficacy of the drug was evaluated, the efficacy rate was 96% for acute sinusitis, 76% for acute exacerbations of chronic sinusitis, 63% for chronic sinusitis, and 84% for all patients.
2) The eradication rate of the isolated bacteria was 91% for Gram-positive bacteria, 100% for gram-negative bacteria, and 94% for all isolates.
3) The improvement rate (the percentage of patients who showed at least a mild improvements) of the X-ray findings was 69%.
4) Side effects were noted in 2 (3%) of 59 patients, and abnomal laboratory findings M1 (3%) of 30 patients, but none were of any particular clinical significance.
5) The safety rate was 95% (56/59).
6) The usefulness rate was 83% (43/52).
Based on these findings RIPM-AC is thus considered to be highly useful for the treatment of sinusitis.